High CD4-to-CD8 ratio identifies an at-risk population susceptible to lethal COVID-19
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00159816%3A_____%2F22%3A00077555" target="_blank" >RIV/00159816:_____/22:00077555 - isvavai.cz</a>
Alternative codes found
RIV/00023736:_____/22:00013322 RIV/00216224:14110/22:00125332
Result on the web
<a href="https://onlinelibrary.wiley.com/doi/10.1111/sji.13125" target="_blank" >https://onlinelibrary.wiley.com/doi/10.1111/sji.13125</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1111/sji.13125" target="_blank" >10.1111/sji.13125</a>
Alternative languages
Result language
angličtina
Original language name
High CD4-to-CD8 ratio identifies an at-risk population susceptible to lethal COVID-19
Original language description
Around half of people with severe COVID-19 requiring intensive care unit (ICU) treatment will survive, but it is unclear how the immune response to SARS-CoV-2 differs between ICU patients that recover and those that do not. We conducted whole-blood immunophenotyping of COVID-19 patients upon admission to ICU and during their treatment and uncovered marked differences in their circulating immune cell subsets. At admission, patients who later succumbed to COVID-19 had significantly lower frequencies of all memory CD8+ T cell subsets, resulting in increased CD4-to-CD8 T cell and neutrophil-to-CD8 T cell ratios. ROC and Kaplan-Meier analyses demonstrated that both CD4-to-CD8 and neutrophil-to-CD8 ratios at admission were strong predictors of in-ICU mortality. Therefore, we propose the use of the CD4-to-CD8 T cell ratio as a marker for the early identification of those individuals likely to require enhanced monitoring and/or pro-active intervention in ICU.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30102 - Immunology
Result continuities
Project
Result was created during the realization of more than one project. More information in the Projects tab.
Continuities
P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)
Others
Publication year
2022
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Scandinavian Journal of Immunology
ISSN
0300-9475
e-ISSN
1365-3083
Volume of the periodical
95
Issue of the periodical within the volume
3
Country of publishing house
GB - UNITED KINGDOM
Number of pages
11
Pages from-to
nestrankovano
UT code for WoS article
000729621000001
EID of the result in the Scopus database
—